171 related articles for article (PubMed ID: 11221872)
1. Identification of a cytotoxic T lymphocyte response to the apoptosis inhibitor protein survivin in cancer patients.
Andersen MH; Pedersen LO; Becker JC; Straten PT
Cancer Res; 2001 Feb; 61(3):869-72. PubMed ID: 11221872
[TBL] [Abstract][Full Text] [Related]
2. Spontaneous cytotoxic T-cell responses against survivin-derived MHC class I-restricted T-cell epitopes in situ as well as ex vivo in cancer patients.
Andersen MH; Pedersen LO; Capeller B; Bröcker EB; Becker JC; thor Straten P
Cancer Res; 2001 Aug; 61(16):5964-8. PubMed ID: 11507035
[TBL] [Abstract][Full Text] [Related]
3. Tumor-reactive, SSX-2-specific CD8+ T cells are selectively expanded during immune responses to antigen-expressing tumors in melanoma patients.
Ayyoub M; Rimoldi D; Guillaume P; Romero P; Cerottini JC; Valmori D; Speiser D
Cancer Res; 2003 Sep; 63(17):5601-6. PubMed ID: 14500401
[TBL] [Abstract][Full Text] [Related]
4. An HLA-A24-restricted cytotoxic T lymphocyte epitope of a tumor-associated protein, survivin.
Hirohashi Y; Torigoe T; Maeda A; Nabeta Y; Kamiguchi K; Sato T; Yoda J; Ikeda H; Hirata K; Yamanaka N; Sato N
Clin Cancer Res; 2002 Jun; 8(6):1731-9. PubMed ID: 12060610
[TBL] [Abstract][Full Text] [Related]
5. Generation of survivin-specific CD8+ T effector cells by dendritic cells pulsed with protein or selected peptides.
Schmitz M; Diestelkoetter P; Weigle B; Schmachtenberg F; Stevanovic S; Ockert D; Rammensee HG; Rieber EP
Cancer Res; 2000 Sep; 60(17):4845-9. PubMed ID: 10987296
[TBL] [Abstract][Full Text] [Related]
6. Identification of a promiscuous HLA DR-restricted T-cell epitope derived from the inhibitor of apoptosis protein survivin.
Piesche M; Hildebrandt Y; Zettl F; Chapuy B; Schmitz M; Wulf G; Trümper L; Schroers R
Hum Immunol; 2007 Jul; 68(7):572-6. PubMed ID: 17584578
[TBL] [Abstract][Full Text] [Related]
7. Two proliferation-related proteins, TYMS and PGK1, could be new cytotoxic T lymphocyte-directed tumor-associated antigens of HLA-A2+ colon cancer.
Shichijo S; Azuma K; Komatsu N; Ito M; Maeda Y; Ishihara Y; Itoh K
Clin Cancer Res; 2004 Sep; 10(17):5828-36. PubMed ID: 15355913
[TBL] [Abstract][Full Text] [Related]
8. Melanoma patients respond to a cytotoxic T lymphocyte-defined self-peptide with diverse and nonoverlapping T-cell receptor repertoires.
Dietrich PY; Walker PR; Quiquerez AL; Perrin G; Dutoit V; Liénard D; Guillaume P; Cerottini JC; Romero P; Valmori D
Cancer Res; 2001 Mar; 61(5):2047-54. PubMed ID: 11280765
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of serine-peptidase activity enhances the generation of a survivin-derived HLA-A2-presented CTL epitope in colon-carcinoma cells.
Preta G; Marescotti D; Fortini C; Carcoforo P; Castelli C; Masucci M; Gavioli R
Scand J Immunol; 2008 Dec; 68(6):579-88. PubMed ID: 19000094
[TBL] [Abstract][Full Text] [Related]
10. A potent immunogenic general cancer vaccine that targets survivin, an inhibitor of apoptosis proteins.
Idenoue S; Hirohashi Y; Torigoe T; Sato Y; Tamura Y; Hariu H; Yamamoto M; Kurotaki T; Tsuruma T; Asanuma H; Kanaseki T; Ikeda H; Kashiwagi K; Okazaki M; Sasaki K; Sato T; Ohmura T; Hata F; Yamaguchi K; Hirata K; Sato N
Clin Cancer Res; 2005 Feb; 11(4):1474-82. PubMed ID: 15746049
[TBL] [Abstract][Full Text] [Related]
11. Identification and characterization of survivin-derived H-2Kb-restricted CTL epitopes.
Hofmann UB; Voigt H; Andersen MH; Straten PT; Becker JC; Eggert AO
Eur J Immunol; 2009 May; 39(5):1419-24. PubMed ID: 19337999
[TBL] [Abstract][Full Text] [Related]
12. Full-length dominant-negative survivin for cancer immunotherapy.
Pisarev V; Yu B; Salup R; Sherman S; Altieri DC; Gabrilovich DI
Clin Cancer Res; 2003 Dec; 9(17):6523-33. PubMed ID: 14695157
[TBL] [Abstract][Full Text] [Related]
13. Characterization of HLA-A3-restricted cytotoxic T lymphocytes reactive against the widely expressed tumor antigen telomerase.
Vonderheide RH; Anderson KS; Hahn WC; Butler MO; Schultze JL; Nadler LM
Clin Cancer Res; 2001 Nov; 7(11):3343-8. PubMed ID: 11705846
[TBL] [Abstract][Full Text] [Related]
14. Identification of a new shared HLA-A2.1 restricted epitope from the melanoma antigen tyrosinase.
Riley JP; Rosenberg SA; Parkhurst MR
J Immunother; 2001; 24(3):212-20. PubMed ID: 11394498
[TBL] [Abstract][Full Text] [Related]
15. NY-ESO-1 119-143 is a promiscuous major histocompatibility complex class II T-helper epitope recognized by Th1- and Th2-type tumor-reactive CD4+ T cells.
Zarour HM; Maillere B; Brusic V; Coval K; Williams E; Pouvelle-Moratille S; Castelli F; Land S; Bennouna J; Logan T; Kirkwood JM
Cancer Res; 2002 Jan; 62(1):213-8. PubMed ID: 11782380
[TBL] [Abstract][Full Text] [Related]
16. Human CTL epitopes prostatic acid phosphatase-3 and six-transmembrane epithelial antigen of prostate-3 as candidates for prostate cancer immunotherapy.
Machlenkin A; Paz A; Bar Haim E; Goldberger O; Finkel E; Tirosh B; Volovitz I; Vadai E; Lugassy G; Cytron S; Lemonnier F; Tzehoval E; Eisenbach L
Cancer Res; 2005 Jul; 65(14):6435-42. PubMed ID: 16024648
[TBL] [Abstract][Full Text] [Related]
17. Cutting edge: rapid cloning of tumor-specific CTL suitable for adoptive immunotherapy of melanoma.
Dunbar PR; Chen JL; Chao D; Rust N; Teisserenc H; Ogg GS; Romero P; Weynants P; Cerundolo V
J Immunol; 1999 Jun; 162(12):6959-62. PubMed ID: 10358133
[TBL] [Abstract][Full Text] [Related]
18. Identification of antigenic epitopes recognized by Mac-2 binding protein-specific cytotoxic T lymphocytes for use in cancer immunotherapy.
Ozaki Y; Kontani K; Teramoto K; Fujita T; Tezuka N; Sawai S; Watanabe H; Fujino S; Asai T; Ohkubo I
Biochem Biophys Res Commun; 2004 May; 317(4):1089-95. PubMed ID: 15094380
[TBL] [Abstract][Full Text] [Related]
19. Identification of novel survivin-derived CTL epitopes.
Reker S; Meier A; Holten-Andersen L; Svane IM; Becker JC; thor Straten P; Andersen MH
Cancer Biol Ther; 2004 Feb; 3(2):173-9. PubMed ID: 14726703
[TBL] [Abstract][Full Text] [Related]
20. Aberrant expression and potency as a cancer immunotherapy target of inhibitor of apoptosis protein family, Livin/ML-IAP in lung cancer.
Hariu H; Hirohashi Y; Torigoe T; Asanuma H; Hariu M; Tamura Y; Aketa K; Nabeta C; Nakanishi K; Kamiguchi K; Mano Y; Kitamura H; Kobayashi J; Tsukahara T; Shijubo N; Sato N
Clin Cancer Res; 2005 Feb; 11(3):1000-9. PubMed ID: 15709165
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
